Statements (30)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
gptkb:drug
small molecule |
| gptkbp:approvalYear |
2020
|
| gptkbp:approvedBy |
gptkb:European_Union
gptkb:Japan |
| gptkbp:ATCCode |
L04AA45
|
| gptkbp:brand |
Jyseleca
|
| gptkbp:CASNumber |
1206161-97-8
|
| gptkbp:chemicalClass |
pyrrolopyrimidine derivative
|
| gptkbp:compatibleWith |
gptkb:United_States
|
| gptkbp:developedBy |
gptkb:Galapagos_NV
gptkb:Gilead_Sciences |
| gptkbp:hasMolecularFormula |
C21H23N5O3
|
| gptkbp:hasSMILES |
CC1=CC(=O)N(C2=NC=NC3=C2N=C(C=C3)N4CCN(CC4)C(=O)C)C1
|
| https://www.w3.org/2000/01/rdf-schema#label |
filgotinib
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:mechanismOfAction |
Janus kinase 1 inhibitor
|
| gptkbp:molecularWeight |
397.44 g/mol
|
| gptkbp:pregnancyCategory |
not recommended
|
| gptkbp:routeOfAdministration |
oral
|
| gptkbp:sideEffect |
nausea
headache infections increased liver enzymes |
| gptkbp:usedFor |
ulcerative colitis
rheumatoid arthritis |
| gptkbp:bfsParent |
gptkb:Galapagos_NV
gptkb:Janus_kinases gptkb:targeted_synthetic_DMARDs |
| gptkbp:bfsLayer |
8
|